Our data, which could potentially change clinical indication to local therapies in oligoprogressive breast cancer, support the notion that HER2+ subtype breast cancer patients could indeed benefit from SBRT in the oligoprogressive setting, particularly during first-line therapy. The gene discussed is ERBB2; the disease is breast cancer.